Sep 28

Scientific

SS 16 - Early Stage and Locally Advanced NSCLC

10:45am - 12:00pm ET

Lung Cancer/Thoracic Malignancies

MODERATOR(S)

Kenneth Olivier, MD, FASTRO - Mayo Clinic

Henry Park, MD, MPH - Yale University

Credits

AMA PRA Category 1 Credits:

1.25

Rate This Session

Presentations

10:45am - 10:55am ET

"No Phase III? No Worries!": Analysis of over 1100 Inoperable Early-Stage Lung Cancer Patients Treated with Either Single- or Three-Fraction SBRT to Reveal a Standard of Care

Speaker: Gregory Videtic, MD, FASTRO, CM, FRCPC, FACR, FASTRO - Cleveland Clinic, Cleveland Heights
10:55am - 11:05am ET

A Dose Escalation Study of Papaverine As a Selective Hypoxic Radiosensitizer for Lung Stereotactic Body Radiation Therapy (SBRT) In the Treatment of Early-Stage Non-Small Cell Lung Cancer (NSCLC) and Other Malignancies

Speaker: Jeremy Brownstein, MD, MS - Ohio State University James Cancer Hospital, Columbus
11:05am - 11:15am ET

Selective Personalized RadioImmunotherapy for Locally Advanced Non-Small-Cell Lung Cancer Trial (SPRINT): Long-Term Outcomes

Speaker: Caroline Oska, MD - Montefiore Einstein Comprehensive Cancer Center, Bronx
11:15am - 11:25am ET

Firmonertinib plus Radiotherapy vs. Concurrent Chemoradiotherapy followed by Firmonertinib Consolidation in Unresectable Stage III <em>EGFR</em>-mutant NSCLC: A Randomized Phase 2 Trial

Speaker: Linlin Wang, - Cancer Hospital of Shangdong First Medical University, Jinan
11:25am - 11:35am ET

Risk-Adapted Radiotherapy for Locally Advanced NSCLC: Pooled Analysis of Two Prospective Trials

Speaker: Shumaila Saad, MD - Montefiore Medical Center, Bronx
11:35am - 11:45am ET

Association Between Circulating Immunobiomarkers and Survival In Stage III Non-Small Cell Lung Cancer (NSCLC) Treated with Chemoradiation (CRT): Longitudinal Analyses from NRG-RTOG 0617

Speaker: Joseph Miccio, MD - Penn State Hershey Medical Center, Hershey